Shanghai Genomics, Inc., a leader of the Chinese biopharmaceutical industry, was founded and is managed by biotechnology professionals returning from the United States. Its mission is to develop novel therapeutic solutions for major diseases threatening the Chinese population, such as liver cirrhosis, acute lung injury/fibrosis, and infectious diseases. The first round of investors included two venture capital firms in China, Shanghai Venture Capital and Zhangjiang Hi-Tech Park Corporation. Shanghai Genomics is privately owned and headquartered at Zhangjiang Hi-Tech Park, Pudong New Area of Shanghai, China. The company has 67 employees and occupies a 30,000-square-foot facility. Shanghai Genomics provides contract research services and genomics/proteomics research tools and reagents to biotech/pharmaceutical companies worldwide. The services include antibody production, antibody screening and immunohistochemistry, recombinant protein production and purification, full-length gene cloning, and Q-PCR and PCR-based gene expression profiling.
Dr. Jun Wu is the co-founder of Shanghai Genomics Inc. He attended Shanghai Medical University as a medical student and later continued his undergraduate studies at San Jose State University in the United States. In 1991, he received his B.S. degree in Microbiology and Immunology. In 1997, he received his doctoral degree at University of California, San Francisco. Later, he joined DNAX Research Institute and Rigel Pharmaceuticals. Dr. Wu is an expert in lymphocyte signal transduction and tumor immunology.